Relmada Therapeutics Q3 EPS $(0.30) Misses $(0.04) Estimate
Benzinga Newsdesk 11 months ago
EarningsEarnings MissesNews
Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.04) by 650 percent. This is a 58.33 percent increase over losses of $(0.72) per share
Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.04) by 650 percent. This is a 58.33 percent increase over losses of $(0.72) per share from the same period last year.